Business
Aethlon Medical to Present at the 13th Annual LD Micro Invitational
SAN DIEGO, June 1, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and
About this update from Aethlon Medical, Inc.
[{"type":"text","content":"SAN DIEGO, June 1, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to diagnose and treat cancer and life-threatening infectious diseases, today announced that Guy Cipriani, Senior Vice President and Chief Business Officer, and James Frakes, Chief Financial Officer, will present a company overview at the 13th Annual LD Micro Invitational on Wednesday, June 7, 2023, at 1:30 PM PT.\nManagement will also be participating in one-on-one meetings with investors at this conference being held June 6-8, 2023, in Los Angeles, California. To schedule a meeting with management outside of the conference, contact Susan Noonan at [email protected].\nInterested parties can register to watch the presentation virtually here.\nTo register to attend the LD Micro conference, please contact [email protected].\nAbout Aethlon and the Hemopurifier®\nAethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and harmful exosomes from blood utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases.\nThe Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies.\nAdditional information can be found at www.AethlonMedical.com.\nCompany Contact:Jim FrakesChief Financial OfficerAethlon Medical, Inc. [email protected]\nInvestor Contact:Susan NoonanS.A. Noonan Communications, [email protected] 917-513-5303\n View original content:https://www.prnewswire.com/news-releases/aethlon-m...